GoAI
Get started
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

NASDAQHealthcareMedical - Devices

Open in GoAI

Regular session

$0.9646

+$0.0003 · +0.03%

Aug 24, 12:28 PM ET

LUCD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

34

Weakening

Sentiment

67

Bullish

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Lishan Aklog
Listed since
Oct 14, 2021
Employees
82

Market position

Day range

Current $0.9646

52-week range

Current $0.9646

Open
$0.968
Previous close
$0.9643
Volume
184.54K
0.14× average
Average volume
1.28M
Average daily volume
Market cap
184.02M USD
Beta
1.08
Market reference 1
50-day average
$0.9894
-2.50% below average
200-day average
$1.1187
-13.77% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
102.24M USD
EV / EBITDA
-1.79×
Earnings yield
-52.20%
Free cash flow yield
-41.83%

Profitability & efficiency

Return on equity
-530.45%
Return on assets
-143.43%
Return on invested capital
-135.05%

Financial health

Current ratio
1.31×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1471%-4482%-10435%-16388%Gross margin, FY2021: -17.00%Gross margin, FY2022: -858.62%Gross margin, FY2023: -249.18%Gross margin, FY2024: -90.20%Gross margin, FY2025: -60.26%Operating margin, FY2021: -5483.80%Operating margin, FY2022: -14899.47%Operating margin, FY2023: -1996.79%Operating margin, FY2024: -1059.64%Operating margin, FY2025: -1054.82%Net margin, FY2021: -5615.60%Net margin, FY2022: -14899.47%Net margin, FY2023: -2169.11%Net margin, FY2024: -1047.61%Net margin, FY2025: -1232.68%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -17.00%. Gross margin FY2022 -858.62%. Gross margin FY2023 -249.18%. Gross margin FY2024 -90.20%. Gross margin FY2025 -60.26%. Operating margin FY2021 -5483.80%. Operating margin FY2022 -14899.47%. Operating margin FY2023 -1996.79%. Operating margin FY2024 -1059.64%. Operating margin FY2025 -1054.82%. Net margin FY2021 -5615.60%. Net margin FY2022 -14899.47%. Net margin FY2023 -2169.11%. Net margin FY2024 -1047.61%. Net margin FY2025 -1232.68%.

Income trends

Revenue

4.71M USD+8.28%

Operating income

−49.64M USD-7.79%

Net income

−58.01M USD-27.41%
Income trends across reported periods10.98M USD−14.11M USD−39.2M USD−64.28M USDRevenue, FY2021: 500K USDRevenue, FY2022: 377K USDRevenue, FY2023: 2.43M USDRevenue, FY2024: 4.35M USDRevenue, FY2025: 4.71M USDOperating income, FY2021: −27.42M USDOperating income, FY2022: −56.17M USDOperating income, FY2023: −48.48M USDOperating income, FY2024: −46.05M USDOperating income, FY2025: −49.64M USDNet income, FY2021: −28.08M USDNet income, FY2022: −56.17M USDNet income, FY2023: −52.67M USDNet income, FY2024: −45.53M USDNet income, FY2025: −58.01M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 500K USD. Revenue FY2022 377K USD. Revenue FY2023 2.43M USD. Revenue FY2024 4.35M USD. Revenue FY2025 4.71M USD. Operating income FY2021 −27.42M USD. Operating income FY2022 −56.17M USD. Operating income FY2023 −48.48M USD. Operating income FY2024 −46.05M USD. Operating income FY2025 −49.64M USD. Net income FY2021 −28.08M USD. Net income FY2022 −56.17M USD. Net income FY2023 −52.67M USD. Net income FY2024 −45.53M USD. Net income FY2025 −58.01M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.71M USD4.35M USD2.43M USD377K USD500K USD
Cost of goods sold7.54M USD8.27M USD8.48M USD3.61M USD585K USD
Gross profit−2.84M USD−3.92M USD−6.05M USD−3.24M USD−85K USD
Research and development5.68B USD5.99M USD7.25M USD11.47M USD9.3M USD
Selling, general, and administrative41.58B USD36.62B USD35.66M USD39.82M USD18.04M USD
Operating expenses46.8M USD42.13M USD42.43M USD52.93M USD27.33M USD
Interest income386K USD322K USD424K USD88K USD—
Interest expense22K USD26K USD416K USD8K USD659K USD
Depreciation and amortization872K USD1.17M USD2.5M USD1.94M USD4K USD
Operating income−49.64M USD−46.05M USD−48.48M USD−56.17M USD−27.42M USD
Net income−58.01M USD−45.53M USD−52.67M USD−56.17M USD−28.08M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.69
FY2025
Latest fiscal-year revenue
4.71M USD
FY2025 · +8.28% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.6-0.95-1.29-1.64FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend5.14M3.41M1.68M-55.9KFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$2.00

107.34% upside
Past 12 months12-month forecastHigh $2.00Average $2.00Low $2.00

Recent analyst actions

6 institutions
Maxim GroupmaintainBuy

LUCD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.73

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.43

-0.47%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.21

+0.03%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.96

-0.49%

Sanofi logo

SNY

Sanofi

$45.6371

-0.46%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$824.47

-1.15%

ETFs holding LUCD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.96M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.57-0.18%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.37M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.38-0.53%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.62M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.8-0.70%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.34M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$383.96-0.88%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
727.75K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.63-0.51%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
500.98K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$196.82-0.66%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
140.38K
Weight
0.01%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$280.3-0.86%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
68.07K
Weight
—
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$116.84-0.58%

Continue in GoAI

Research LUCD

research.disclaimer